Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 31, 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan. This resulted in an increase in the notional allocation of American Depositary Shares (ADSs) on March 28, 2014, at a price of $53.90 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investors to Verify
- The transaction involved a notional increase of 4 ADSs for Dr. K. Slaoui, a connected person.
- Dr. M. Slaoui, a Director, had no change in notional ADS allocation (-).
- The transaction price was $53.90 per ADS.
- The notification was issued by the Company Secretary, Victoria Whyte, on March 31, 2014.